GAITHERSBURG, Md., Oct. 30, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that it will report its financial results for the third quarter of 2014 on Wednesday, November 5, 2014, after market close.
In addition, management will host a conference call, to discuss the quarterly financial results and provide an update on corporate activities.
Conference call details are as follows:
|Date:||November 5, 2014|
|Time:||4:30 PM US eastern time|
|Dial-in number:||1 (877) 212-6076 (domestic) or 1 (707) 287-9331 (international)|
Conference call replay:
|Dates:||Starting at 6:31pm on November 5, 2014 until midnight November 12, 2014|
|Dial-in number:||1 (855) 859-2056 (domestic) or 1 (404) 537-3406 (international)|
|Via-Web:||www.novavax.com, "Investor Info"/"Events"|
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biopharmaceutical company creating novel vaccines and vaccine adjuvants to address a broad range of infectious diseases worldwide. Using innovative proprietary recombinant protein nanoparticle vaccine technology, the company produces vaccine candidates to efficiently and effectively respond to both known and newly emergent diseases. Additional information about Novavax is available on the company's website, novavax.com.
CONTACT: Barclay Phillips SVP, Chief Financial Officer and Treasurer Novavax, Inc. 240-268-2000